{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T08:44:08Z","timestamp":1794473048957,"version":"4.9.1"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100006955","name":"U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA229261"],"award-info":[{"award-number":["R01 CA229261"]}],"id":[{"id":"10.13039\/100006955","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Biotechnol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1038\/s41587-026-03018-2","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T10:01:44Z","timestamp":1773136904000},"page":"740-751","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The promises and challenges of neoantigen cancer vaccines"],"prefix":"10.1038","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4253-943X","authenticated-orcid":false,"given":"Patrick A.","family":"Ott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"key":"3018_CR1","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1158\/2159-8290.CD-25-0300","volume":"15","author":"DJ Martini","year":"2025","unstructured":"Martini, D. J. & Wu, C. J. The future of personalized cancer vaccines. Cancer Discov. 15, 1315\u20131324 (2025).","journal-title":"Cancer Discov."},{"key":"3018_CR2","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41576-019-0166-7","volume":"20","author":"F Finotello","year":"2019","unstructured":"Finotello, F., Rieder, D., Hackl, H. & Trajanoski, Z. Next-generation computational tools for interrogating cancer immunity. Nat. Rev. Genet. 20, 724\u2013746 (2019).","journal-title":"Nat. Rev. Genet."},{"key":"3018_CR3","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41587-019-0322-9","volume":"38","author":"S Sarkizova","year":"2020","unstructured":"Sarkizova, S. et al. A large peptidome dataset improves HLA class I epitope prediction across most of the human population. Nat. Biotechnol. 38, 199\u2013209 (2020).","journal-title":"Nat. Biotechnol."},{"key":"3018_CR4","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1073\/pnas.74.1.272","volume":"74","author":"T Boon","year":"1977","unstructured":"Boon, T. & Kellermann, O. Rejection by syngeneic mice of cell variants obtained by mutagenesis of a malignant teratocarcinoma cell line. Proc. Natl Acad. Sci. USA 74, 272\u2013275 (1977).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3018_CR5","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","volume":"23","author":"K Karik\u00f3","year":"2005","unstructured":"Karik\u00f3, K., Buckstein, M., Ni, H. & Weissman, D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23, 165\u2013175 (2005).","journal-title":"Immunity"},{"key":"3018_CR6","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1038\/s41565-019-0591-y","volume":"14","author":"A Akinc","year":"2019","unstructured":"Akinc, A. et al. The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. Nat. Nanotechnol. 14, 1084\u20131087 (2019).","journal-title":"Nat. Nanotechnol."},{"key":"3018_CR7","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1056\/NEJMc2115597","volume":"385","author":"LR Baden","year":"2021","unstructured":"Baden, L. R. et al. Phase 3 trial of mRNA-1273 during the Delta-variant surge. N. Engl. J. Med. 385, 2485\u20132487 (2021).","journal-title":"N. Engl. J. Med."},{"key":"3018_CR8","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1158\/2159-8290.CD-20-1575","volume":"11","author":"RG Gupta","year":"2021","unstructured":"Gupta, R. G., Li, F., Roszik, J. & Liz\u00e9e, G. Exploiting tumor neoantigens to target cancer evolution: current challenges and promising therapeutic approaches. Cancer Discov. 11, 1024\u20131039 (2021).","journal-title":"Cancer Discov."},{"key":"3018_CR9","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1016\/j.cell.2022.06.035","volume":"185","author":"MC Sellars","year":"2022","unstructured":"Sellars, M. C., Wu, C. J. & Fritsch, E. F. Cancer vaccines: building a bridge over troubled waters. Cell 185, 2770\u20132788 (2022).","journal-title":"Cell"},{"key":"3018_CR10","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1038\/s41590-019-0441-y","volume":"20","author":"V Verma","year":"2019","unstructured":"Verma, V. et al. PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance. Nat. Immunol. 20, 1231\u20131243 (2019).","journal-title":"Nat. Immunol."},{"key":"3018_CR11","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","volume":"391","author":"CU Blank","year":"2024","unstructured":"Blank, C. U. et al. Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma. N. Engl. J. Med. 391, 1696\u20131708 (2024).","journal-title":"N. Engl. J. Med."},{"key":"3018_CR12","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1056\/NEJMoa2211437","volume":"388","author":"SP Patel","year":"2023","unstructured":"Patel, S. P. et al. Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma. N. Engl. J. Med. 388, 813\u2013823 (2023).","journal-title":"N. Engl. J. Med."},{"key":"3018_CR13","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","volume":"389","author":"JV Heymach","year":"2023","unstructured":"Heymach, J. V. et al. Perioperative durvalumab for resectable non-small-cell lung cancer. N. Engl. J. Med. 389, 1672\u20131684 (2023).","journal-title":"N. Engl. J. Med."},{"key":"3018_CR14","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1056\/NEJMoa2415434","volume":"393","author":"R Uppaluri","year":"2025","unstructured":"Uppaluri, R. et al. Neoadjuvant and adjuvant pembrolizumab in locally advanced head and neck cancer. N. Engl. J. Med. 393, 37\u201350 (2025).","journal-title":"N. Engl. J. Med."},{"key":"3018_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.762796","volume":"9","author":"S Zhou","year":"2021","unstructured":"Zhou, S., Fan, C., Zeng, Z., Young, K. H. & Li, Y. Clinical and immunological effects of p53-targeting vaccines. Front. Cell Dev. Biol. 9, 762796 (2021).","journal-title":"Front. Cell Dev. Biol."},{"key":"3018_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11091460","volume":"11","author":"F Li","year":"2023","unstructured":"Li, F. et al. Epidermal growth factor receptor-targeted neoantigen peptide vaccination for the treatment of non-small cell lung cancer and glioblastoma. Vaccines (Basel) 11, 1460 (2023).","journal-title":"Vaccines"},{"key":"3018_CR17","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41591-023-02760-3","volume":"30","author":"S Pant","year":"2024","unstructured":"Pant, S. et al. Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial. Nat. Med. 30, 531\u2013542 (2024).","journal-title":"Nat. Med."},{"key":"3018_CR18","doi-asserted-by":"publisher","first-page":"3648","DOI":"10.1038\/s41591-025-03876-4","volume":"31","author":"ZA Wainberg","year":"2025","unstructured":"Wainberg, Z. A. et al. Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results. Nat. Med. 31, 3648\u20133653 (2025).","journal-title":"Nat. Med."},{"key":"3018_CR19","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/s41591-024-02851-9","volume":"30","author":"AR Rappaport","year":"2024","unstructured":"Rappaport, A. R. et al. A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results. Nat. Med. 30, 1013\u20131022 (2024).","journal-title":"Nat. Med."},{"key":"3018_CR20","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/bs.mcb.2023.05.002","volume":"183","author":"K Godazandeh","year":"2024","unstructured":"Godazandeh, K. et al. Methods behind neoantigen prediction for personalized anticancer vaccines. Methods Cell. Biol. 183, 161\u2013186 (2024).","journal-title":"Methods Cell. Biol."},{"key":"3018_CR21","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ccell.2022.10.013","volume":"41","author":"L Lybaert","year":"2023","unstructured":"Lybaert, L. et al. Challenges in neoantigen-directed therapeutics. Cancer Cell 41, 15\u201340 (2023).","journal-title":"Cancer Cell"},{"key":"3018_CR22","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41573-021-00387-y","volume":"21","author":"F Lang","year":"2022","unstructured":"Lang, F., Schr\u00f6rs, B., L\u00f6wer, M., T\u00fcreci, \u00d6. & Sahin, U. Identification of neoantigens for individualized therapeutic cancer vaccines. Nat. Rev. Drug Discov. 21, 261\u2013282 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"3018_CR23","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.cell.2020.09.015","volume":"183","author":"DK Wells","year":"2020","unstructured":"Wells, D. K. et al. Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction. Cell 183, 818\u2013834 (2020).","journal-title":"Cell"},{"key":"3018_CR24","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.it.2025.06.002","volume":"46","author":"G Goncalves","year":"2025","unstructured":"Goncalves, G., Dolcetti, R., Ooi, J. D. & Faridi, P. Cryptic but critical: non-canonical antigens in cancer immunotherapy. Trends Immunol. 46, 499\u2013501 (2025).","journal-title":"Trends Immunol."},{"key":"3018_CR25","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ads7405","volume":"11","author":"R Raja","year":"2025","unstructured":"Raja, R. et al. Immunogenic cryptic peptides dominate the antigenic landscape of ovarian cancer. Sci. Adv. 11, eads7405 (2025).","journal-title":"Sci. Adv."},{"key":"3018_CR26","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1038\/s43018-025-00979-2","volume":"6","author":"A Apavaloaei","year":"2025","unstructured":"Apavaloaei, A. et al. Tumor antigens preferentially derive from unmutated genomic sequences in melanoma and non-small cell lung cancer. Nat. Cancer 6, 1419\u20131437 (2025).","journal-title":"Nat. Cancer"},{"key":"3018_CR27","doi-asserted-by":"publisher","DOI":"10.1126\/science.adk3487","volume":"388","author":"ZA Ely","year":"2025","unstructured":"Ely, Z. A. et al. Pancreatic cancer-restricted cryptic antigens are targets for T cell recognition. Science 388, eadk3487 (2025).","journal-title":"Science"},{"key":"3018_CR28","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abm6359","volume":"8","author":"A Merlotti","year":"2023","unstructured":"Merlotti, A. et al. Noncanonical splicing junctions between exons and transposable elements represent a source of immunogenic recurrent neo-antigens in patients with lung cancer. Sci. Immunol. 8, eabm6359 (2023).","journal-title":"Sci. Immunol."},{"key":"3018_CR29","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1016\/j.cell.2025.01.046","volume":"188","author":"Q Jiang","year":"2025","unstructured":"Jiang, Q. et al. HIF regulates multiple translated endogenous retroviruses: implications for cancer immunotherapy. Cell 188, 1807\u20131827 (2025).","journal-title":"Cell"},{"key":"3018_CR30","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403\u2013416 (2021).","journal-title":"N. Engl. J. Med."},{"key":"3018_CR31","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1084\/jem.20101158","volume":"208","author":"MS Diamond","year":"2011","unstructured":"Diamond, M. S. et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J. Exp. Med. 208, 1989\u20132003 (2011).","journal-title":"J. Exp. Med."},{"key":"3018_CR32","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/nature18300","volume":"534","author":"LM Kranz","year":"2016","unstructured":"Kranz, L. M. et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature 534, 396\u2013401 (2016).","journal-title":"Nature"},{"key":"3018_CR33","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/s41573-025-01237-x","volume":"24","author":"S Wang","year":"2025","unstructured":"Wang, S., Weissman, D. & Dong, Y. RNA chemistry and therapeutics. Nat. Rev. Drug Discov. 24, 828\u2013851 (2025).","journal-title":"Nat. Rev. Drug Discov."},{"key":"3018_CR34","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1038\/s41594-020-0465-x","volume":"27","author":"L Jia","year":"2020","unstructured":"Jia, L. et al. Decoding mRNA translatability and stability from the 5\u2019UTR. Nat. Struct. Mol. Biol. 27, 814\u2013821 (2020).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"3018_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-00950-y","volume":"7","author":"E Fang","year":"2022","unstructured":"Fang, E. et al. Advances in COVID-19 mRNA vaccine development. Signal Transduct. Target. Ther. 7, 94 (2022).","journal-title":"Signal Transduct. Target. Ther."},{"key":"3018_CR36","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/s41587-019-0164-5","volume":"37","author":"PJ Sample","year":"2019","unstructured":"Sample, P. J. et al. Human 5\u2019UTR design and variant effect prediction from a massively parallel translation assay. Nat. Biotechnol. 37, 803\u2013809 (2019).","journal-title":"Nat. Biotechnol."},{"key":"3018_CR37","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/s41586-023-06127-z","volume":"621","author":"H Zhang","year":"2023","unstructured":"Zhang, H. et al. Algorithm for optimized mRNA design improves stability and immunogenicity. Nature 621, 396\u2013403 (2023).","journal-title":"Nature"},{"key":"3018_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49508-2","volume":"15","author":"S Castillo-Hair","year":"2024","unstructured":"Castillo-Hair, S. et al. Optimizing 5\u2019UTRs for mRNA-delivered gene editing using deep learning. Nat. Commun. 15, 5284 (2024).","journal-title":"Nat. Commun."},{"key":"3018_CR39","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.ads1328","volume":"10","author":"EA Aunins","year":"2025","unstructured":"Aunins, E. A. et al. An Il12 mRNA-LNP adjuvant enhances mRNA vaccine-induced CD8 T cell responses. Sci. Immunol. 10, eads1328 (2025).","journal-title":"Sci. Immunol."},{"key":"3018_CR40","doi-asserted-by":"publisher","first-page":"10708","DOI":"10.1073\/pnas.1408677111","volume":"111","author":"DY Kim","year":"2014","unstructured":"Kim, D. Y. et al. Enhancement of protein expression by alphavirus replicons by designing self-replicating subgenomic RNAs. Proc. Natl Acad. Sci. USA 111, 10708\u201310713 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"3018_CR41","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/s41417-022-00435-8","volume":"30","author":"P Aliahmad","year":"2023","unstructured":"Aliahmad, P., Miyake-Stoner, S. J., Geall, A. J. & Wang, N. S. Next generation self-replicating RNA vectors for vaccines and immunotherapies. Cancer Gene Ther. 30, 785\u2013793 (2023).","journal-title":"Cancer Gene Ther."},{"key":"3018_CR42","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1038\/s41591-022-01937-6","volume":"28","author":"CD Palmer","year":"2022","unstructured":"Palmer, C. D. et al. Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results. Nat. Med. 28, 1619\u20131629 (2022).","journal-title":"Nat. Med."},{"key":"3018_CR43","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/nchembio.2318","volume":"13","author":"AJ Mijalis","year":"2017","unstructured":"Mijalis, A. J. et al. A fully automated flow-based approach for accelerated peptide synthesis. Nat. Chem. Biol. 13, 464\u2013466 (2017).","journal-title":"Nat. Chem. Biol."},{"key":"3018_CR44","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nmat4822","volume":"16","author":"R Kuai","year":"2017","unstructured":"Kuai, R., Ochyl, L. J., Bahjat, K. S., Schwendeman, A. & Moon, J. J. Designer vaccine nanodiscs for personalized cancer immunotherapy. Nat. Mater. 16, 489\u2013496 (2017).","journal-title":"Nat. Mater."},{"key":"3018_CR45","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/s41587-019-0390-x","volume":"38","author":"GM Lynn","year":"2020","unstructured":"Lynn, G. M. et al. Peptide-TLR-7\/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens. Nat. Biotechnol. 38, 320\u2013332 (2020).","journal-title":"Nat. Biotechnol."},{"key":"3018_CR46","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41590-020-00810-3","volume":"22","author":"F Baharom","year":"2021","unstructured":"Baharom, F. et al. Intravenous nanoparticle vaccination generates stem-like TCF1+ neoantigen-specific CD8+ T cells. Nat. Immunol. 22, 41\u201352 (2021).","journal-title":"Nat. Immunol."},{"key":"3018_CR47","doi-asserted-by":"publisher","first-page":"4317","DOI":"10.1016\/j.cell.2022.10.006","volume":"185","author":"F Baharom","year":"2022","unstructured":"Baharom, F. et al. Systemic vaccination induces CD8+ T cells and remodels the tumor microenvironment. Cell 185, 4317\u20134332 (2022).","journal-title":"Cell"},{"key":"3018_CR48","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1021\/acscentsci.3c00625","volume":"9","author":"NL Truex","year":"2023","unstructured":"Truex, N. L. et al. Enhanced vaccine immunogenicity enabled by targeted cytosolic delivery of tumor antigens into dendritic cells. ACS Cent. Sci. 9, 1835\u20131845 (2023).","journal-title":"ACS Cent. Sci."},{"key":"3018_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-022-00503-y","volume":"7","author":"T Travieso","year":"2022","unstructured":"Travieso, T., Li, J., Mahesh, S., Mello, J. D. F. R. E. & Blasi, M. The use of viral vectors in vaccine development. NPJ Vaccines 7, 75 (2022).","journal-title":"NPJ Vaccines"},{"key":"3018_CR50","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1016\/j.ymthe.2025.04.008","volume":"33","author":"PS Bhojnagarwala","year":"2025","unstructured":"Bhojnagarwala, P. S., Jose, J., Zhao, S. & Weiner, D. B. DNA-based immunotherapy for cancer: in vivo approaches for recalcitrant targets. Mol. Ther. 33, 2719\u20132739 (2025).","journal-title":"Mol. Ther."},{"key":"3018_CR51","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.coi.2020.01.006","volume":"65","author":"EN Gary","year":"2020","unstructured":"Gary, E. N. & Weiner, D. B. DNA vaccines: prime time is now. Curr. Opin. Immunol. 65, 21\u201327 (2020).","journal-title":"Curr. Opin. Immunol."},{"key":"3018_CR52","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1126\/science.aaa3828","volume":"348","author":"BM Carreno","year":"2015","unstructured":"Carreno, B. M. et al. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 348, 803\u2013808 (2015).","journal-title":"Science"},{"key":"3018_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101516","volume":"5","author":"J Ingels","year":"2024","unstructured":"Ingels, J. et al. Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum. Cell Rep. Med. 5, 101516 (2024).","journal-title":"Cell Rep. Med."},{"key":"3018_CR54","doi-asserted-by":"publisher","first-page":"3972","DOI":"10.1158\/0008-5472.CAN-20-1072","volume":"80","author":"G Leoni","year":"2020","unstructured":"Leoni, G. et al. A genetic vaccine encoding shared cancer neoantigens to treat tumors with microsatellite instability. Cancer Res. 80, 3972\u20133982 (2020).","journal-title":"Cancer Res."},{"key":"3018_CR55","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature22991","volume":"547","author":"PA Ott","year":"2017","unstructured":"Ott, P. A. et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 547, 217\u2013221 (2017).","journal-title":"Nature"},{"key":"3018_CR56","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature23003","volume":"547","author":"U Sahin","year":"2017","unstructured":"Sahin, U. et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 547, 222\u2013226 (2017).","journal-title":"Nature"},{"key":"3018_CR57","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/s41586-018-0810-y","volume":"565","author":"N Hilf","year":"2019","unstructured":"Hilf, N. et al. Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature 565, 240\u2013245 (2019).","journal-title":"Nature"},{"key":"3018_CR58","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","volume":"565","author":"DB Keskin","year":"2019","unstructured":"Keskin, D. B. et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature 565, 234\u2013239 (2019).","journal-title":"Nature"},{"key":"3018_CR59","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/j.ccell.2022.08.003","volume":"40","author":"MM Awad","year":"2022","unstructured":"Awad, M. M. et al. Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer. Cancer Cell 40, 1010\u20131026 (2022).","journal-title":"Cancer Cell"},{"key":"3018_CR60","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.cell.2020.08.053","volume":"183","author":"PA Ott","year":"2020","unstructured":"Ott, P. A. et al. A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. Cell 183, 347\u2013362 (2020).","journal-title":"Cell"},{"key":"3018_CR61","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1158\/2159-8290.CD-24-0934","volume":"15","author":"M Saxena","year":"2025","unstructured":"Saxena, M. et al. PGV001, a multi-peptide personalized neoantigen vaccine platform: phase I study in patients with solid and hematologic malignancies in the adjuvant setting. Cancer Discov. 15, 930\u2013947 (2025).","journal-title":"Cancer Discov."},{"key":"3018_CR62","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1038\/s43018-025-00966-7","volume":"6","author":"M Saxena","year":"2025","unstructured":"Saxena, M. et al. Atezolizumab plus personalized neoantigen vaccination in urothelial cancer: a phase 1 trial. Nat. Cancer 6, 988\u2013999 (2025).","journal-title":"Nat. Cancer"},{"key":"3018_CR63","doi-asserted-by":"publisher","first-page":"5125","DOI":"10.1016\/j.cell.2025.06.019","volume":"188","author":"E Blass","year":"2025","unstructured":"Blass, E. et al. A multi-adjuvant personal neoantigen vaccine generates potent immunity in melanoma. Cell 188, 5125\u20135141 (2025).","journal-title":"Cell"},{"key":"3018_CR64","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41591-024-03334-7","volume":"31","author":"J Lopez","year":"2025","unstructured":"Lopez, J. et al. Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial. Nat. Med. 31, 152\u2013164 (2025).","journal-title":"Nat. Med."},{"key":"3018_CR65","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/s41591-024-02894-y","volume":"30","author":"M Yarchoan","year":"2024","unstructured":"Yarchoan, M. et al. Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1\/2 trial. Nat. Med. 30, 1044\u20131053 (2024).","journal-title":"Nat. Med."},{"key":"3018_CR66","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-024-01388-3","volume":"16","author":"X Zhang","year":"2024","unstructured":"Zhang, X. et al. Neoantigen DNA vaccines are safe, feasible, and induce neoantigen-specific immune responses in triple-negative breast cancer patients. Genome Med. 16, 131 (2024).","journal-title":"Genome Med."},{"key":"3018_CR67","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","volume":"403","author":"JS Weber","year":"2024","unstructured":"Weber, J. S. et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet 403, 632\u2013644 (2024).","journal-title":"Lancet"},{"key":"3018_CR68","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas, L. A. et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 618, 144\u2013150 (2023).","journal-title":"Nature"},{"key":"3018_CR69","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/s41586-024-08508-4","volume":"639","author":"Z Sethna","year":"2025","unstructured":"Sethna, Z. et al. RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. Nature 639, 1042\u20131051 (2025).","journal-title":"Nature"},{"key":"3018_CR70","doi-asserted-by":"publisher","first-page":"S623","DOI":"10.1016\/j.annonc.2025.08.1523","volume":"36","author":"RJ Sullivan","year":"2025","unstructured":"Sullivan, R. J. et al. 954P a randomized phase II study of autogene cevumeran plus pembrolizumab (pembro) versus pembro in 1L advanced melanoma (IMcode001). Ann. Oncol. 36, S623\u2013S624 (2025).","journal-title":"Ann. Oncol."},{"key":"3018_CR71","doi-asserted-by":"publisher","first-page":"4035","DOI":"10.1182\/bloodadvances.2022007792","volume":"8","author":"CA Ramirez","year":"2024","unstructured":"Ramirez, C. A. et al. Neoantigen landscape supports feasibility of personalized cancer vaccine for follicular lymphoma. Blood Adv. 8, 4035\u20134049 (2024).","journal-title":"Blood Adv."},{"key":"3018_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50880-2","volume":"15","author":"SJ Szymura","year":"2024","unstructured":"Szymura, S. J. et al. Personalized neoantigen vaccines as early intervention in untreated patients with lymphoplasmacytic lymphoma: a non-randomized phase 1 trial. Nat. Commun. 15, 6874 (2024).","journal-title":"Nat. Commun."},{"key":"3018_CR73","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-017-0468-3","volume":"9","author":"TC Chang","year":"2017","unstructured":"Chang, T. C. et al. The neoepitope landscape in pediatric cancers. Genome Med. 9, 78 (2017).","journal-title":"Genome Med."},{"key":"3018_CR74","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.immuni.2021.03.001","volume":"54","author":"G Ehx","year":"2021","unstructured":"Ehx, G. et al. Atypical acute myeloid leukemia-specific transcripts generate shared and immunogenic MHC class-I-associated epitopes. Immunity 54, 737\u2013752 (2021).","journal-title":"Immunity"},{"key":"3018_CR75","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41586-024-08507-5","volume":"639","author":"DA Braun","year":"2025","unstructured":"Braun, D. A. et al. A neoantigen vaccine generates antitumour immunity in renal cell carcinoma. Nature 639, 474\u2013482 (2025).","journal-title":"Nature"},{"key":"3018_CR76","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1158\/2159-8290.CD-24-0158","volume":"14","author":"JF Gainor","year":"2024","unstructured":"Gainor, J. F. et al. T-cell responses to individualized neoantigen therapy mRNA-4157 (V940) alone or in combination with pembrolizumab in the phase 1 KEYNOTE-603 study. Cancer Discov. 14, 2209\u20132223 (2024).","journal-title":"Cancer Discov."}],"container-title":["Nature Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41587-026-03018-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41587-026-03018-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41587-026-03018-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T22:04:53Z","timestamp":1779055493000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41587-026-03018-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":76,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["3018"],"URL":"https:\/\/doi.org\/10.1038\/s41587-026-03018-2","relation":{},"ISSN":["1087-0156","1546-1696"],"issn-type":[{"value":"1087-0156","type":"print"},{"value":"1546-1696","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"assertion":[{"value":"11 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.A.O. has received research funding from, and\/or has advised, Agenus, Arcturus, Amgen, Armo BioSciences, Array, AstraZeneca\/MedImmune, Bristol Myers Squibb, Celldex, CytomX, Evaxion, Immunetune, Imunon, LG Chem, Merck, Moderna, Neon Therapeutics (now BioNTech US), Novartis, PharmaJet, Phio, Pfizer, Oncorus, Roche\/Genentech, Servier and Xencor.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}